CEO Michel Detheux was paid $6,085,657 in fiscal year 2024, ↑ up 5.5% from fiscal year 2023 (SEC filing 0000950170-25-057666 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$6,085,657 ↑ Michel Detheux total, FY2024 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michel Detheux | $628,684 | $0 | $0 | $4,965,264 | $421,014 | $0 | $70,695 | $6,085,657 |
| Chief Executive Officer | ||||||||
| David Feltquate | 214,271 | 0 | 391,040 | 4,189,500 | 250,320 | 0 | 9,874 | 5,055,005 |
| Chief Medical Officer | ||||||||
| Matthew Call | 491,734 | 0 | 0 | 1,892,250 | 215,777 | 0 | 17,970 | 2,617,730 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Michel Detheux | $6,085,657 | $5,767,774 | — | ↑ +317,883 |
| David Feltquate | 5,055,005 | — | — | — |
| Matthew Call | 2,617,730 | 2,803,174 | — | ↓ −185,444 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read iTeos Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ITOS reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name ITOS as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2024 total |
|---|---|---|
| Aaron Davis | Former director (through FY2024) | $280,962 |
| Ann D. Rhoads | Independent Director | $345,566 |
| David K. Lee | Independent Director | $320,072 |
| David L. Hallal | Chair of the Board | $442,822 |
| Jill DeSimone | Independent Director | $686,270 |
| Robert Iannone | Independent Director | $341,264 |
| Tim Van Hauwermeiren | Independent Director | $331,566 |
| Tony Ho | Independent Director | $332,764 |
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Tim van Hauwermeiren | Director | 2025-05-13 | A | 22,346 | $4 | $96,088 | Common | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | — | 2025-05-13 | D | 630,191 | 8 | 5,079,339 | Common, indirect | Form 4 ↗ |
| Ansbert Gadicke | — | 2025-05-13 | D | 1,031,931 | 8 | 8,317,364 | Common, indirect | Form 4 ↗ |
| Tim van Hauwermeiren | Director | 2025-05-13 | D | 22,346 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | — | 2025-05-13 | D | 630,191 | 8 | 5,079,339 | Common, indirect | Form 4 ↗ |
| EcoR1 Capital, LLC | Greater-than-10% holder | 2025-05-14 | A | 1,658,978 | 7 | 12,285,562 | Common | Form 4 ↗ |
| EcoR1 Capital, LLC | Greater-than-10% holder | 2025-05-15 | A | 3,300,000 | 8 | 26,400,000 | Common | Form 4 ↗ |
| David L. Hallal | Director | 2025-06-04 | A | 38,227 | 4 | 164,376 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-04 | A | 8,400 | 4 | 36,120 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-04 | D | 43,883 | 10 | 443,218 | Common | Form 4 ↗ |
| David L. Hallal | Director | 2025-06-04 | D | 38,227 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David L. Hallal | Director | 2025-06-04 | D | 38,227 | 10 | 384,946 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-04 | D | 43,883 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-04 | D | 8,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-04 | A | 43,883 | 4 | 188,697 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-04 | D | 8,400 | 10 | 84,840 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-05 | D | 8,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-05 | D | 43,882 | 10 | 445,402 | Common | Form 4 ↗ |
| David L. Hallal | Director | 2025-06-05 | D | 38,227 | 10 | 388,004 | Common | Form 4 ↗ |
| David L. Hallal | Director | 2025-06-05 | D | 38,227 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David L. Hallal | Director | 2025-06-05 | A | 38,227 | 4 | 164,376 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-05 | D | 43,882 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-05 | A | 43,882 | 4 | 188,693 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-05 | D | 8,400 | 10 | 85,260 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-05 | A | 8,400 | 4 | 36,120 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-06 | D | 8,400 | 10 | 85,764 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-06 | D | 43,882 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-06 | D | 43,882 | 10 | 448,035 | Common | Form 4 ↗ |
| David L. Hallal | Director | 2025-06-06 | D | 38,228 | 10 | 391,455 | Common | Form 4 ↗ |
| David L. Hallal | Director | 2025-06-06 | D | 38,228 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David L. Hallal | Director | 2025-06-06 | A | 38,228 | 4 | 164,380 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-06 | D | 8,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-06 | A | 43,882 | 4 | 188,693 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-06 | A | 8,400 | 4 | 36,120 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-09 | D | 43,882 | 10 | 440,136 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-09 | D | 43,882 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-09 | D | 8,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-09 | D | 8,400 | 10 | 84,252 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-09 | A | 43,882 | 4 | 188,693 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-09 | A | 8,400 | 4 | 36,120 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-10 | A | 8,400 | 4 | 36,120 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-10 | D | 18,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-10 | A | 43,883 | 4 | 188,697 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-10 | D | 8,400 | 10 | 84,168 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-10 | D | 94,027 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-10 | D | 43,883 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-10 | D | 43,883 | 10 | 439,708 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-10 | D | 8,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-10 | A | 94,027 | 4 | 404,316 | Common | Form 4 ↗ |
| Michel Detheux | Chief Executive Officer | 2025-06-10 | A | 18,000 | 4 | 77,400 | Common | Form 4 ↗ |
| Michel Detheux | Director | 2025-08-29 | D | 153,903 | — | — | Common | Form 4 ↗ |
| David K. Lee | Director | 2025-08-29 | D | 21,141 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Director | 2025-08-29 | D | 50,128 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Director | 2025-08-29 | D | 94,336 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Call | Chief Operating Officer | 2025-08-29 | D | 161,898 | — | — | Common | Form 4 ↗ |
| Michel Detheux | Director | 2025-08-29 | D | 52,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Call | Chief Operating Officer | 2025-08-29 | D | 146,835 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Director | 2025-08-29 | D | 185,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Director | 2025-08-29 | D | 94,027 | — | — | Common | Form 4 ↗ |
| Matthew Call | Chief Operating Officer | 2025-08-29 | D | 41,694 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Call | Chief Operating Officer | 2025-08-29 | D | 135,937 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David L. Hallal | Director | 2025-08-29 | D | 25,140 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yvonne McGrath | Chief Scientific Officer | 2025-08-29 | D | 46,300 | — | — | Common | Form 4 ↗ |
| Matthew Gall | Chief Financial Officer | 2025-08-29 | D | 42,388 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Gall | Chief Financial Officer | 2025-08-29 | D | 9,063 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Feltquate | Chief Medical Officer | 2025-08-29 | D | 47,000 | — | — | Common | Form 4 ↗ |
| David K. Lee | Director | 2025-08-29 | D | 23,625 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Director | 2025-08-29 | D | 17,544 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Call | Chief Operating Officer | 2025-08-29 | D | 17,074 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Call | Chief Operating Officer | 2025-08-29 | D | 66,170 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David L. Hallal | Director | 2025-08-29 | D | 146,160 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ann D. Rhoads | Director | 2025-08-29 | D | 27,178 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yvonne McGrath | Chief Scientific Officer | 2025-08-29 | D | 16,054 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yvonne McGrath | Chief Scientific Officer | 2025-08-29 | D | 69,069 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yvonne McGrath | Chief Scientific Officer | 2025-08-29 | D | 91,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Gall | Chief Financial Officer | 2025-08-29 | D | 252,135 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Gall | Chief Financial Officer | 2025-08-29 | D | 8,123 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michel Detheux | Director | 2025-08-29 | D | 14,185 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Call | Chief Operating Officer | 2025-08-29 | D | 9,063 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Gall | Chief Financial Officer | 2025-08-29 | D | 89,429 | — | — | Common | Form 4 ↗ |
| Michel Detheux | Director | 2025-08-29 | D | 444,815 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Gall | Chief Financial Officer | 2025-08-29 | D | 135,937 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Michel Detheux | OPTION | 2024-03-07 | — | — | 590,400 | — | $4,965,264 |
| Matthew Call | OPTION | 2024-03-07 | — | — | 225,000 | — | 1,892,250 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Michel Detheux | $0 | $0 | $4,965,264 | 0.0% |
| Matthew Call | 0 | 0 | 1,892,250 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Matthew Call | Option | 9,000 | 23.19 | — |
| Michel Detheux | RSU | 3,125 | — | 24,000 |
| Matthew Call | Option | 26,562 | 36.21 | — |
| David Feltquate | RSU | 47,000 | — | 360,960 |
| Michel Detheux | Option | 194,626 | 16.66 | — |
| Michel Detheux | Option | 110,156 | 36.21 | — |
| Matthew Call | Option | 225,000 | 11.58 | — |
| Matthew Call | Option | 73,125 | 16.66 | — |
| Matthew Call | RSU | 44,000 | — | 337,920 |
| Michel Detheux | Option | 9,000 | 41.58 | — |
| Matthew Call | Option | 4,500 | 41.58 | — |
| Michel Detheux | RSU | 30,000 | — | 230,400 |
| Michel Detheux | Option | 590,400 | 11.58 | — |
| David Feltquate | Option | 350,000 | 17.46 | — |
Compensation for executive officers consists primarily of base salary, certain bonus opportunities, and equity incentives. The company aims to offer compensation that is competitive and aligned with business and executive talent requirements, considering individual contribution, role, and performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-17 | — | — | — | — | — |
| 2024 | 2024-06-11 | — | — | — | — | — |
| 2023 | 2023-06-13 | — | — | — | — | — |
| 2022 | 2022-06-09 | — | — | — | — | — |
| 2021 | 2021-06-16 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-06-17 | —a |
| 2024 | 2024-06-11 | —b |
| 2023 | 2023-06-13 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jill DeSimoneIndependent | $28,826 | $0 | $657,444 | $0 | $0 | $686,270 |
| David L. HallalIndependent | 161,860 | 0 | 280,962 | 0 | 0 | 442,822 |
| Ann D. RhoadsIndependent | 64,604 | 0 | 280,962 | 0 | 0 | 345,566 |
| Robert IannoneIndependent | 60,302 | 0 | 280,962 | 0 | 0 | 341,264 |
| Tony HoIndependent | 51,802 | 0 | 280,962 | 0 | 0 | 332,764 |
| Tim van HauwermeirenIndependent | 50,604 | 0 | 280,962 | 0 | 0 | 331,566 |
| David K. LeeIndependent | 39,110 | 0 | 280,962 | 0 | 0 | 320,072 |
| Aaron DavisIndependent | 0 | 0 | 280,962 | 0 | 0 | 280,962 |
| Michel DetheuxEmployee director · Science and Technology | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $457,108 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $457,108 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | iTeos Therapeutics | 2024 | Michel Detheux | $628,684 | $0 | $4,965,264 | $421,014 | $6,085,657 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Michel Detheux | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Executive Compensation”. As printed: 6,085,657. Filing ↗machine: r2 · c27 · span 499272–499281 |
| 2 | Section 01, David Feltquate | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Executive Compensation”. As printed: 5,055,005. Filing ↗machine: r6 · c27 · span 536184–536193 |
| 3 | Section 01, Matthew Call | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Executive Compensation”. As printed: 2,617,730. Filing ↗machine: r4 · c27 · span 517603–517612 |
| 4 | Section 03, Michel Detheux OPTION | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t10 · r2 · c13 · span 456007–456016 |
| 5 | Section 03, Matthew Call OPTION | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t10 · r3 · c13 · span 463687–463696 |
| 6 | Section 08, Jill DeSimone | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Director Compensation”. As printed: 686,270. Filing ↗machine: span 370269–370478 |
| 7 | Section 08, David L. Hallal | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Director Compensation”. As printed: 442,822. Filing ↗machine: span 375781–375990 |
| 8 | Section 08, Ann D. Rhoads | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Director Compensation”. As printed: 345,566. Filing ↗machine: span 403327–403536 |
| 9 | Section 08, Robert Iannone | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Director Compensation”. As printed: 341,264. Filing ↗machine: span 392310–392519 |
| 10 | Section 08, Tony Ho | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Director Compensation”. As printed: 332,764. Filing ↗machine: span 386800–387009 |
| 11 | Section 08, Tim van Hauwermeiren | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Director Compensation”. As printed: 331,566. Filing ↗machine: span 381297–381506 |
| 12 | Section 08, David K. Lee | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Director Compensation”. As printed: 320,072. Filing ↗machine: span 397818–398027 |
| 13 | Section 08, Aaron Davis | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Director Compensation”. As printed: 280,962. Filing ↗machine: span 362213–362422 |
| 14 | Section 08, Michel Detheux | DEF 14A | 2025-04-24 | 0000950170-25-057666 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 02, Tim van Hauwermeiren 2025-05-13 | Form 4 | 2025-05-14 | 0000950170-25-071755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, MPM BIOVENTURES 2018, L.P. 2025-05-13 | Form 4 | 2025-05-15 | 0001415889-25-013251 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Ansbert Gadicke 2025-05-13 | Form 4 | 2025-05-15 | 0001415889-25-013252 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Tim van Hauwermeiren 2025-05-13 | Form 4 | 2025-05-14 | 0000950170-25-071755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, MPM BioVentures 2014, L.P. 2025-05-13 | Form 4 | 2025-05-15 | 0001415889-25-013248 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, EcoR1 Capital, LLC 2025-05-14 | Form 4 | 2025-05-16 | 0000935836-25-000384 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, EcoR1 Capital, LLC 2025-05-15 | Form 4 | 2025-05-16 | 0000935836-25-000384 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, David L. Hallal 2025-06-04 | Form 4 | 2025-06-06 | 0000950170-25-083410 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Michel Detheux 2025-06-04 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Michel Detheux 2025-06-04 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, David L. Hallal 2025-06-04 | Form 4 | 2025-06-06 | 0000950170-25-083410 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, David L. Hallal 2025-06-04 | Form 4 | 2025-06-06 | 0000950170-25-083410 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Michel Detheux 2025-06-04 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Michel Detheux 2025-06-04 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Michel Detheux 2025-06-04 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Michel Detheux 2025-06-04 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Michel Detheux 2025-06-05 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Michel Detheux 2025-06-05 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, David L. Hallal 2025-06-05 | Form 4 | 2025-06-06 | 0000950170-25-083410 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, David L. Hallal 2025-06-05 | Form 4 | 2025-06-06 | 0000950170-25-083410 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, David L. Hallal 2025-06-05 | Form 4 | 2025-06-06 | 0000950170-25-083410 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Michel Detheux 2025-06-05 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Michel Detheux 2025-06-05 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Michel Detheux 2025-06-05 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Michel Detheux 2025-06-05 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Michel Detheux 2025-06-06 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Michel Detheux 2025-06-06 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Michel Detheux 2025-06-06 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, David L. Hallal 2025-06-06 | Form 4 | 2025-06-06 | 0000950170-25-083410 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, David L. Hallal 2025-06-06 | Form 4 | 2025-06-06 | 0000950170-25-083410 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, David L. Hallal 2025-06-06 | Form 4 | 2025-06-06 | 0000950170-25-083410 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Michel Detheux 2025-06-06 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Michel Detheux 2025-06-06 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Michel Detheux 2025-06-06 | Form 4 | 2025-06-06 | 0000950170-25-083411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Michel Detheux 2025-06-09 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Michel Detheux 2025-06-09 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Michel Detheux 2025-06-09 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Michel Detheux 2025-06-09 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Michel Detheux 2025-06-09 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Michel Detheux 2025-06-09 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Michel Detheux 2025-06-10 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Michel Detheux 2025-06-10 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Michel Detheux 2025-06-10 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Michel Detheux 2025-06-10 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Michel Detheux 2025-06-10 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Michel Detheux 2025-06-10 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Michel Detheux 2025-06-10 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Michel Detheux 2025-06-10 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Michel Detheux 2025-06-10 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Michel Detheux 2025-06-10 | Form 4 | 2025-06-11 | 0000950170-25-085047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Michel Detheux 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112240 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, David K. Lee 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112239 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Michel Detheux 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112240 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Michel Detheux 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112240 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Matthew Call 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112241 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Michel Detheux 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112240 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Matthew Call 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112241 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Michel Detheux 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112240 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Michel Detheux 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112240 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Matthew Call 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112241 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Matthew Call 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112241 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, David L. Hallal 2025-08-29 | Form 4 | 2025-08-29 | 0001193125-25-192818 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Yvonne McGrath 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112235 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Matthew Gall 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112236 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Matthew Gall 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112236 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, David Feltquate 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112238 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, David K. Lee 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112239 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Michel Detheux 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112240 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Matthew Call 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112241 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Matthew Call 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112241 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, David L. Hallal 2025-08-29 | Form 4 | 2025-08-29 | 0001193125-25-192818 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Ann D. Rhoads 2025-08-29 | Form 4 | 2025-08-29 | 0001193125-25-192817 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Yvonne McGrath 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112235 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Yvonne McGrath 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112235 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Yvonne McGrath 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112235 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Matthew Gall 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112236 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Matthew Gall 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112236 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Michel Detheux 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112240 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Matthew Call 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112241 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Matthew Gall 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112236 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Michel Detheux 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112240 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Matthew Gall 2025-08-29 | Form 4 | 2025-08-29 | 0000950170-25-112236 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 06, 2025 vote | Form 8-K | 2025-06-17 | 0000950170-25-087429 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 98 | Section 06, 2024 vote | Form 8-K | 2024-06-13 | 0000950170-24-072973 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 99 | Section 06, 2023 vote | Form 8-K | 2023-06-20 | 0000950170-23-028774 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 100 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 101 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 102 | Section 09b board cost (computed) | Computed | — | — | Cash 457,108 + equity 0 + all other 0 = 457,108, summed across the director compensation table rows.machine: formula: Σ = 457,108 |
| 103 | iTeos Therapeutics (subject), Section 10b CEO total | DEF 14A | 2025-04-24 | 0000950170-25-057666 | CEO total compensation as printed in iTeos Therapeutics's own proxy. As printed: 6,085,657. Filing ↗machine: r2 · c27 · span 499272–499281 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.